CTRI/2014/12/005269已完成未知
An open-label, randomized, single dose, three-way cross over, six sequence pilot study to determine the relative bioavailability of candesartan cilexetil 16mg from two candidate tablet formulations of GW615775 relative to one 16mg tablet of reference candesartan cilexetil in healthy adult human subjects under fasting conditions - Asian
GlaxoSmithKline Research and Development Limited0 个研究点目标入组 18 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Male and females aged between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- •-Healthy as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •-Body weight >= 50 kg and BMI within the range 19 â?? 24.9 kg/m2 (inclusive).
- •Female subject: is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies.
- •Non-reproductive potential defined as
- •Pre-menopausal females with one of the following
- •Documented tubal ligation
- •Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
- •Hysterectomy
- •Documented bilateral oophorectomy
- •Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause [refer to laboratory reference ranges for confirmatory levels]). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment
- •Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until [at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer] after the last dose of study medication and completion of the follow-up visit
排除标准
- •Hypersensitivity to candesartan cilexetil or to any of the excipients
研究者
相似试验
招募中
不适用
Relative bioavailability of montelukast sodium 5mg from two candidate chewable tablet formulations of GW483100 relative to one 5mg chewable tablet of reference montelukast sodium in healthy adult subjects under fasting conditionsCTRI/2015/03/005625GlaxoSmithKline Research and Development Limited18
已完成
不适用
Relative bioavailability study of two candidate formulations of GR107719B (Mosapride 5 mg) under fasting conditionsCTRI/2014/01/004318GlaxoSmithKline Research and Development Limited18
已完成
不适用
Relative bioavailability of clopidogrel 75mg from two tablet formulations of SB224326 relative to one 75mg reference tablet of clopidogrel in healthy adult human subjects under fasting conditionsCTRI/2016/04/006789GlaxoSmithKline Research and Development Limited18
已完成
不适用
A clinical trial to investigate the pharmacokinetic drug-drug interaction of Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteersKCT0000763Ildong pharmaceutical54
进行中（未招募）
不适用
Clinical study to test that the drug CHF 1535 100/6 (fixed combination of an anti-inflammatory drug and relaxing airways drug) delivered via pressurized inhaler using or not a spacer device is as effective in adolescent population as the licensed free combination of the same substances and compare it with administration in adults.MedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2011-005108-14-PLChiesi Farmaceutici S.p.A.